{"id":147766,"date":"2017-05-23T14:38:34","date_gmt":"2017-05-23T14:38:34","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=147766"},"modified":"2017-05-23T14:38:34","modified_gmt":"2017-05-23T14:38:34","slug":"amcham-arpim-taxa-clawback-este-una-dintre-masurile-care-descurajeaza-investitiile-in-romania","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=147766","title":{"rendered":"AmCham &#038; ARPIM &#8211; \u201eTaxa clawback este una dintre m\u0103surile care descurajeaz\u0103 investi\u0163iile \u00een Rom\u00e2nia\u201d"},"content":{"rendered":"<p>\n\u201eLipsa de predictibilitate a mecanismului clawback, corelat\u0103 cu nivelul nesustenabil din punct de vedere economic pentru industria farmaceutic\u0103 din Rom\u00e2nia, impune o revizuire a acestui sistem. Trebuie evitat orice risc de restric\u0163ionare a accesului pacien\u0163ilor rom\u00e2ni la tratamente moderne prin retragerea de pe pia\u0163\u0103 a unor medicamente sau diminuarea lans\u0103rii de produse noi. Recomand\u0103m alinierea contribu\u0163iei clawback cu practica european\u0103 \u00een domeniu astfel \u00eenc\u00e2t aceasta s\u0103 devin\u0103 un instrument de control al consumului exagerat de medicamente, f\u0103r\u0103 a se transfera sectorului privat diferen\u0163a dintre consumul real al pacien\u0163ilor \u015fi bugetul insuficient pentru tratamente\u201d, a precizat Anda Todor, Pre\u015fedinte al Grupului de S\u0103n\u0103tate din AmCham.&nbsp;<\/p>\n<p>\n\u201eS\u0103 nu uit\u0103m c\u0103 taxa clawback a fost impus\u0103 ca o m\u0103sur\u0103 de control bugetar \u00een perioad\u0103 de criz\u0103. \u00cen condi\u0163iile \u00een care Rom\u00e2nia se afl\u0103 \u00een plin\u0103 cre\u015ftere economic\u0103 nu se mai justific\u0103 nevoia de a obliga produc\u0103torii de medicamente s\u0103-\u015fi asume responsabilitatea trat\u0103rii pacien\u0163ilor al c\u0103ror tratament nu se \u00eencadreaz\u0103 \u00een bugetul alocat de autorit\u0103\u0163i pentru medicamente. Taxa clawback, \u00een valoare de 19,86%, este cu patru puncte procentuale mai mare \u00een acest trimestru comparativ cu acela\u015fi trimestru al anului trecut. Nu este echitabil\u0103, nu este predictibil\u0103, creeaz\u0103 dezechilibre financiare care pot pune \u00een pericol accesul pacien\u0163ilor la tratamente inovatoare, multe dintre ele f\u0103r\u0103 alternativ\u0103 terapeutic\u0103 \u00een pia\u0163\u0103\u201d, a ad\u0103ugat C\u0103lin G\u0103l\u0103\u015feanu, Pre\u015fedinte al Local American Working Group (LAWG).<\/p>\n<p>\n\u201eIndustria farmaceutic\u0103 \u00ee\u015fi dore\u015fte s\u0103 investeasc\u0103 \u00een Rom\u00e2nia, \u00eens\u0103 reglement\u0103rile din sistemul de s\u0103n\u0103tate, coroborate, descurajeaz\u0103 orice investi\u0163ie prin crearea unui mediu de business ostil. Produc\u0103torii pl\u0103tesc aproape 20% din valoarea medicamentelor decontate de CNAS, suprataxare care se calculeaz\u0103 \u00een func\u0163ie de bugetul medicamentelor r\u0103mas la nivelul anului 2011. Mai mult, taxa clawback se calculeaz\u0103 la pre\u0163ul medicamentelor la raft care include \u015fi adaosurile distribuitorilor \u015fi farmaciilor, o povar\u0103 suplimentar\u0103 pentru produc\u0103torii de medicamente. Metodologia de calcul al pre\u0163urilor impune un pre\u0163 minim european care va sc\u0103dea cu 35% pentru medicamentele ie\u015fite de sub patent \u015fi care va cre\u015fte riscul dispari\u0163iei medicamentelor de pe pia\u0163\u0103.&nbsp; Noile medicamente ajung cu dificultate la pacien\u0163i. Nu exist\u0103 premisele cre\u015fterii investi\u0163iilor \u00een Rom\u00e2nia \u00een lipsa unor solu\u0163ii eficiente \u015fi echitabile care s\u0103 \u00eembun\u0103t\u0103\u0163easc\u0103 accesul pacien\u0163ilor la medicamente \u015fi s\u0103 creeze un mediu de business transparent \u015fi predictibil\u201d, a afirmat Dan Zaharescu, Directorul Executiv al Asocia\u0163iei Rom\u00e2ne a Produc\u0103torilor Interna\u0163ionali de Medicamente din Rom\u00e2nia (ARPIM).<\/p>\n<p>\nInvestitorii \u00een sectorul farmaceutic \u00ee\u015fi exprim\u0103 deschiderea de a colabora cu autorit\u0103\u0163ile pentru a implementa un mecanism de contribu\u0163ie care s\u0103 asigure sustenabilitate financiar\u0103 pentru bugetul public, asigur\u00e2nd \u00een acela\u015fi timp accesul rapid al pacien\u0163ilor la tratament \u015fi sporind astfel atractivitatea Rom\u00e2niei pentru investi\u0163ii viitoare. Companiile membre ale acestor asocia\u0163ii sunt deschise dialogului \u015fi colabor\u0103rii cu autorit\u0103\u0163ile pentru a identifica un mecanism eficient \u015fi echitabil de calcul al taxei clawback, dar \u015fi pentru a g\u0103si solu\u0163ii care s\u0103 creasc\u0103 poten\u0163ialul Rom\u00e2niei de a atrage investi\u0163ii str\u0103ine.<\/p>\n<p>\n&nbsp;<\/p>\n<p>\n&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Camera de Comer\u0163 American\u0103 \u00een Rom\u00e2nia (AmCham), Asocia\u0163ia Rom\u00e2n\u0103 a Produc\u0103torilor Interna\u0163ionali de Medicamente (ARPIM) \u015fi Local American Working Group (LAWG) subliniaz\u0103 faptul c\u0103 taxa clawback, coroborat\u0103 cu toate celelalte reglement\u0103ri din industria farmaceutic\u0103 descurajeaz\u0103 investi\u0163iile \u00een Rom\u00e2nia.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[238,12870,10412,10313,74,24895,240,246,31465,474,149,10898,323,408,60,7147,80,7207,9184,13481,98,34613,12923],"class_list":["post-147766","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-acces","tag-american","tag-asociatie","tag-autoritati","tag-buget","tag-clawback","tag-comert","tag-crestere","tag-impunere","tag-industrie","tag-investitii","tag-masuri","tag-medicamente","tag-pacienti","tag-piata","tag-producatori","tag-refuz","tag-reglementari","tag-risc","tag-romana","tag-romania","tag-taxa-clawback","tag-tratament"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/147766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=147766"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/147766\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=147766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=147766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=147766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}